EUVIMEDEUVIMED entdecken
Crossref

Novel Sulfonamide‐Sydnone Hybrids: Complementary Insight into Anti‐Inflammatory Action, Anti‐SARS‐CoV‐2 Activity, Human Serum Albumin Interaction, and in silico Analysis

Igor Resendes Barbosa, Mayara Alves Amorim, Vitor Hélio de Souza Oliveira, Eunice André, Guilherme Pereira Guedes, Otávio Augusto Chaves, Carlos Serpa, Natalia Fintelman-Rodrigues, Carolina Q Sacramento, Thiago Moreno L Souza, Carlos Mauricio R Sant'Anna, Aurea Echevarria iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202400697 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Igor Resendes Barbosa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemistry, Federal Rural University of Rio de Janeiro, Seropédica, 23898-56, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: SARS-CoV-2, Sulfonamides, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 97 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação Carlos Chagas de Amparo à Pesquisa do Estado do Rio de Janeiro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute lung injury (ALI) is a severe condition often seen in intensive care unit patients. Due to limited treatment options, ALI is linked to high rates of mortality and morbidity. Bacterial and viral infections are significant contributors to ALI. For instance, severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2) infection can lead to a strong inflammatory response that may progress to ALI, a leading cause of death in COVID‐19 cases. Prior research has demonstrated that sulfonamides and sydnones exhibit anti‐inflammatory and antiviral properties, which has led us to develop compounds containing both scaffolds. Most of the new sulfonamide‐sydnone hybrids are expected to be orally bioavailable based on in silico ADME predictions. They effectively suppressed the development of ALI in lipopolysaccharide (LPS)‐challenged mice and inhibited viral replication in Calu‐3 cells, with minimal cytotoxicity in non‐infected Calu‐3 and Vero E6 cells. Molecular docking investigations indicated some possible viral targets for the action of the sydnones, highlighting the possible interaction with non‐structural proteins of SARS‐CoV‐2. Additionally, combined experimental and theoretical studies indicated that the new compounds can strongly interact with human serum albumin, suggesting a possible extended residence time in the human bloodstream.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2SulfonamidesAntiviral AgentsCOVID-19 Drug TreatmentSerum Albumin, HumanAnti-Inflammatory AgentsHumansAnimalsMolecular Docking SimulationMiceChlorocebus aethiopsVero CellsLipopolysaccharidesVirus ReplicationCOVID-19Acute Lung Injury

Stichwörter der Autor:innen

Acute lung injuryAlbuminSARS-CoV-2SulfonamidesSydnones

Substanzen

SulfonamidesAntiviral AgentsSerum Albumin, HumanLipopolysaccharidesAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Institute of Chemistry, Federal Rural University of Rio de Janeiro, Seropédica, 23898-56, Rio de Janeiro, Brazil.
  • Department of Pharmacology, Federal University of Paraná, Curitiba, 81531-980, PR, Brazil.
  • Institute of Chemistry, Fluminense Federal University, Niterói, 24020-141, Rio de Janeiro, Brazil.
  • Department of Chemistry, Coimbra Chemistry Centre - Institute of Molecular Science (CQC-IMS), University of Coimbra, Rua Larga, 3004-535, Coimbra, Portugal.
  • Laboratory of Immunopharmacology, Centro de Pesquisa, Inovação e Vigilância em COVID-19 e Emergências Sanitárias (CPIV), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (FIOCRUZ), 21040-361, Rio de Janeiro, RJ, Br…
  • National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, 21040-900, Brazil.

ORCID-Profile: Aurea Echevarria

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação Carlos Chagas de Amparo à Pesquisa do Estado do Rio de Janeiro
  • Fundação Oswaldo Cruz (FIOCRUZ)
  • Fundação para a Ciência e a Tecnologia

Zitieren

APA

Resendes Barbosa, I., Alves Amorim, M., de Souza Oliveira, V. H., André, E., Pereira Guedes, G., Augusto Chaves, O., Serpa, C., Fintelman-Rodrigues, N., Sacramento, C. Q., Moreno L Souza, T., Sant'Anna, C. M. R., & Echevarria, A. (2025). Novel Sulfonamide‐Sydnone Hybrids: Complementary Insight into Anti‐Inflammatory Action, Anti‐SARS‐CoV‐2 Activity, Human Serum Albumin Interaction, and in silico Analysis. ChemMedChem. https://doi.org/10.1002/cmdc.202400697

Vancouver

Resendes Barbosa I, Alves Amorim M, de Souza Oliveira VH, André E, Pereira Guedes G, Augusto Chaves O, et al. Novel Sulfonamide‐Sydnone Hybrids: Complementary Insight into Anti‐Inflammatory Action, Anti‐SARS‐CoV‐2 Activity, Human Serum Albumin Interaction, and in silico Analysis. ChemMedChem. 2025. doi:10.1002/cmdc.202400697

BibTeX
@article{ResendesBarbosa2025,
  author = {Resendes Barbosa, Igor and Alves Amorim, Mayara and de Souza Oliveira, Vitor Hélio and André, Eunice and Pereira Guedes, Guilherme and Augusto Chaves, Otávio and Serpa, Carlos and Fintelman-Rodrigues, Natalia and Sacramento, Carolina Q and Moreno L Souza, Thiago and Sant'Anna, Carlos Mauricio R and Echevarria, Aurea},
  title = {Novel Sulfonamide‐Sydnone Hybrids: Complementary Insight into Anti‐Inflammatory Action, Anti‐SARS‐CoV‐2 Activity, Human Serum Albumin Interaction, and in silico Analysis},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202400697}
}
Kostenlos starten →